FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2799351483> ?p ?o ?g. }

• W2799351483 endingPage "21035" @default.
• W2799351483 startingPage "21022" @default.
• W2799351483 abstract "Dysregulation of cell metabolism is a hallmark of cancer. The mevalonate pathway in lipid metabolism has been implicated as a potential target of cancer therapy for hepatocellular carcinoma (HCC). The role of the Forkhead Box M1 (FoxM1) transcription factor in HCC development has been well documented, however, its involvement in cancer metabolism of HCC has not been fully determined. Here, we hypothesized that FoxM1 is involved in the mevalonate pathway of cholesterol biosynthesis in HCC. Inhibition of the mevalonate pathway by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), resulted in reduced expression of FoxM1 and increased cell death in human hepatoma cells. Re-exposure of mevalonate, a product of HMGCR, restored these effects. Likewise, knockdown of HMGCR reduced FoxM1 expression, indicating that FoxM1 expression was regulated by the mevalonate pathway in HCC. Mechanistically, protein geranylgeranylation was found to be responsible for FoxM1 expression and geranylgeranylated proteins, including RhoA, Rac1 or Cdc42, were shown to be involved in this process. In surgically resected human HCC tissues, the gene expression of FoxM1 had a positive correlation with that of the mevalonate pathway-related genes, such as HMGCR or sterol regulatory element-binding protein 2 (SREBP2). Furthermore, the gene expression of FoxM1 along with that of HMGCR or SREBP2 defined prognosis of HCC patients, suggesting the clinical significance of the mevalonate-FoxM1 pathway in human HCC. Our data indicate that FoxM1 links the mevalonate pathway to oncogenic signals in HCC. Thus, we propose a novel therapeutic approach to inhibit FoxM1 by targeting the mevalonate pathway for HCC." @default.
• W2799351483 created "2018-05-17" @default.
• W2799351483 creator A5014128503 @default.
• W2799351483 creator A5024410377 @default.
• W2799351483 creator A5025096054 @default.
• W2799351483 creator A5025453831 @default.
• W2799351483 creator A5028284770 @default.
• W2799351483 creator A5034357098 @default.
• W2799351483 creator A5040891927 @default.
• W2799351483 creator A5050869638 @default.
• W2799351483 creator A5056018649 @default.
• W2799351483 creator A5064909021 @default.
• W2799351483 creator A5066105203 @default.
• W2799351483 creator A5067647817 @default.
• W2799351483 creator A5073472318 @default.
• W2799351483 creator A5088118861 @default.
• W2799351483 date "2018-04-20" @default.
• W2799351483 modified "2023-10-12" @default.
• W2799351483 title "Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma" @default.
• W2799351483 cites W1840802607 @default.
• W2799351483 cites W1967235705 @default.
• W2799351483 cites W1969711650 @default.
• W2799351483 cites W1970005961 @default.
• W2799351483 cites W1971837077 @default.
• W2799351483 cites W1972926597 @default.
• W2799351483 cites W1984708567 @default.
• W2799351483 cites W1987090100 @default.
• W2799351483 cites W1997986669 @default.
• W2799351483 cites W2002512110 @default.
• W2799351483 cites W2014756186 @default.
• W2799351483 cites W2023859459 @default.
• W2799351483 cites W2034901476 @default.
• W2799351483 cites W2039755487 @default.
• W2799351483 cites W2040292743 @default.
• W2799351483 cites W2049811920 @default.
• W2799351483 cites W2054506782 @default.
• W2799351483 cites W2061743943 @default.
• W2799351483 cites W2071979885 @default.
• W2799351483 cites W2073131803 @default.
• W2799351483 cites W2081832076 @default.
• W2799351483 cites W2092409818 @default.
• W2799351483 cites W2092481295 @default.
• W2799351483 cites W2101516738 @default.
• W2799351483 cites W2115662954 @default.
• W2799351483 cites W2117692326 @default.
• W2799351483 cites W2121215375 @default.
• W2799351483 cites W2122401755 @default.
• W2799351483 cites W2124618775 @default.
• W2799351483 cites W2131668351 @default.
• W2799351483 cites W2134987468 @default.
• W2799351483 cites W2135630561 @default.
• W2799351483 cites W2143036691 @default.
• W2799351483 cites W2149972103 @default.
• W2799351483 cites W2155240851 @default.
• W2799351483 cites W2155421604 @default.
• W2799351483 cites W2158838322 @default.
• W2799351483 cites W2159343393 @default.
• W2799351483 cites W2161425163 @default.
• W2799351483 cites W2161765887 @default.
• W2799351483 cites W2165468042 @default.
• W2799351483 cites W2169300384 @default.
• W2799351483 cites W2171293990 @default.
• W2799351483 cites W2229461735 @default.
• W2799351483 cites W2234453634 @default.
• W2799351483 cites W2341032132 @default.
• W2799351483 cites W2421614151 @default.
• W2799351483 cites W2517092932 @default.
• W2799351483 cites W2550322865 @default.
• W2799351483 cites W2552951299 @default.
• W2799351483 cites W2560499218 @default.
• W2799351483 cites W2796327157 @default.
• W2799351483 cites W4361868990 @default.
• W2799351483 doi "https://doi.org/10.18632/oncotarget.24781" @default.
• W2799351483 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5940385" @default.
• W2799351483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29765517" @default.
• W2799351483 hasPublicationYear "2018" @default.
• W2799351483 type Work @default.
• W2799351483 sameAs 2799351483 @default.
• W2799351483 citedByCount "14" @default.
• W2799351483 countsByYear W27993514832018 @default.
• W2799351483 countsByYear W27993514832019 @default.
• W2799351483 countsByYear W27993514832020 @default.
• W2799351483 countsByYear W27993514832022 @default.
• W2799351483 countsByYear W27993514832023 @default.
• W2799351483 crossrefType "journal-article" @default.
• W2799351483 hasAuthorship W2799351483A5014128503 @default.
• W2799351483 hasAuthorship W2799351483A5024410377 @default.
• W2799351483 hasAuthorship W2799351483A5025096054 @default.
• W2799351483 hasAuthorship W2799351483A5025453831 @default.
• W2799351483 hasAuthorship W2799351483A5028284770 @default.
• W2799351483 hasAuthorship W2799351483A5034357098 @default.
• W2799351483 hasAuthorship W2799351483A5040891927 @default.
• W2799351483 hasAuthorship W2799351483A5050869638 @default.
• W2799351483 hasAuthorship W2799351483A5056018649 @default.
• W2799351483 hasAuthorship W2799351483A5064909021 @default.
• W2799351483 hasAuthorship W2799351483A5066105203 @default.
• W2799351483 hasAuthorship W2799351483A5067647817 @default.
• W2799351483 hasAuthorship W2799351483A5073472318 @default.

• next